BioLamina AB is a Swedish biotechnology company specializing in the development and production of full-length human recombinant laminin substrates under the Biolaminin® brand. Founded in 2008 based on research from the Karolinska Institute into extracellular matrix proteins, the company provides defined, animal origin-free cell culture matrices for 2D and 3D applications.
These substrates enable controlled expansion, maintenance, differentiation, and maturation of pluripotent stem cells, primary cells, and specialized cell types such as hepatocytes, cardiomyocytes, and neurons. Biolaminin products support reproducible research outcomes, improved drug safety testing, and clinical-grade cell production for advanced therapies targeting conditions like type 1 diabetes, Parkinson’s disease, and cancer.
Product lines include Biolaminin LN for research, MX for translational studies, and CTG for clinical use, complying with strict regulatory standards. Headquartered in Sundbyberg near Stockholm, BioLamina recently secured €20 million in venture debt from the European Investment Bank to scale manufacturing and expand its portfolio.
